|Cancer Stem Cell News 7.10 March 14, 2018|
Scientists report that MYC acts as tumor reprogramming factor in mammary epithelial cells by inducing an alternative epigenetic program, which triggers loss of cell identity and activation of oncogenic pathways. [Nat Commun]
Investigators found that PCNA-associated factor (PAF) is expressed in intestinal stem and progenitor cells and markedly upregulated during intestinal regeneration and tumorigenesis. [Dev Cell]
The authors hypothesized that interactions with the extracellular matrix drive CSC proliferation and tumor-initiating capacity and investigated the functions of scaffold protein tissue transglutaminase in ovarian CSC. [Cancer Res]
Researchers report that elevated claudin-2 expression in stage II/III colorectal tumors is associated with poor recurrence-free survival following 5-FU-based chemotherapy, an outcome in which CSC play an instrumental role. [Cancer Res]
3P cells specifically exhibited low E-cadherin expression and high invasiveness, suggesting that they were endowed with the highest malignant characteristics. RNA-sequence analysis demonstrated that distinct signaling pathways were activated in each cell line and that the 3P cells acquired a cancer stem cell-like phenotype. [Oncogene]
The effects of DAX1 silencing on the cell growth, tumor formation, and CSC characteristics were investigated. [Cell Death Dis]
Scientists found that hypoxic tumor cells freshly isolated from xenografts contain increased subpopulations of tumor cells with CSC-like characteristics. [Breast Cancer Res]
Researchers investigated the role of CREB binding protein (CBP)-beta-catenin signaling on the expression of CD133, a known stem cell antigen and PP2A-PTEN pathway in tumor initiating liver cancer cells. [Cell Commun Signal]
Investigators explored the effect of combined use of dabrafenib, a BRAF inhibitor, and cetuximab, an EGFR inhibitor, on BRAF(V600E)-mutant CRC stem cells and its possible mechanisms. [Acta Biochim Biophys Sin]
Glioblastoma multiforme is the most common and aggressive primary brain tumor, with an extremely poor prognosis. The lack of detailed knowledge about the cellular and molecular mechanisms involved in glioblastoma development restricts the design of efficient therapies. [Cancer Med]
Visit our reviews page to see a complete list of reviews in the cancer stem cell research field.
Boehringer Ingelheim and Vanderbilt University announced the expansion of their successful existing collaboration to develop novel anti-cancer compounds. The expanded research partnership will focus on the discovery and development of new chemical therapeutics targeting the pro-survival protein MCL1 as a potential therapy against MCL1-dependent cancers. [Vanderbilt University]
VBL Therapeutics reported top-line results from its pivotal Phase III GLOBE study in patients with recurrent glioblastoma which was designed to evaluate VB-111 in combination with bevacizumab compared to the bevacizumab control arm. The study did not meet its pre-specified primary endpoint of overall survival. [VBL Therapeutics (GlobeNewswire, Inc.)]
GlycoMimetics, Inc. announced its design for a randomized, double-blind, placebo-controlled Phase III clinical trial to evaluate GMI-1271 in combination with mitoxantrone, etoposide and Ara-C, or in combination with fludarabine, cytosine arabinoside and idarubicin in individuals with relapsed/refractory AML. [GlycoMimetics, Inc.]
Van der Heyden isn’t the only European researcher to get a hard sell from Pan European Networks, a six-year-old publishing company with offices in Congleton, U.K., and Brussels that promises to provide opportunities for “leading figures from across Europe” to get attention for their work or ideas. Many other scientists had similar experiences, Van der Heyden discovered when he started poking around on blogs and Twitter, including the promise of attention from decision-makers and the warning about the imminent board meeting. [ScienceInsider]
In a major blow to the effort to pass a federal “right-to-try” law, House Republicans failed to muster the votes to pass a key compromise measure. [STAT News]
Springer Nature and the Association of Universities in the Netherlands (VSNU) have renewed their agreement to secure open access publishing for Dutch universities up to 2021. [The Association of Universities in the Netherlands]
Representative Daniel Lipinski—an anti-abortion Democrat who voted against the Affordable Care Act and who only recently has embraced a path to citizenship for undocumented immigrants—knows that he’s out of step with progressives on many social issues. Lipinski will find out whether voters in Illinois’s third congressional district on Chicago’s southwest side feel there’s still room for him in the Democratic Party. [ScienceInsider]
NEW 6th Cambridge International Stem Cell Symposium
Visit our events page to see a complete list of events in the community.
Have we missed an important article or publication in Cancer Stem Cell News? Click here to submit!
Comments or suggestions? Submit your feedback here.